Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News PDS Biotechnology Corp PDSB

Healthcare Biotechnology
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PDSB)

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

GlobeNewswire March 27, 2024

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

GlobeNewswire March 20, 2024

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

GlobeNewswire March 13, 2024

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

GlobeNewswire January 22, 2024

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

GlobeNewswire January 16, 2024

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2023

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

GlobeNewswire November 28, 2023

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 14, 2023

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

GlobeNewswire November 9, 2023
View More News ››

Opinion & Analysis (NDAQ:PDSB)

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

Streetwise Reports October 4, 2019
View More Opinion ››

Bullboard Posts (NDAQ:PDSB)

Very interesting .....

Pre-market open is showing a possible reversal on this. I have an interesting analogy to day trading....and believe it or not ....it...
Iseneschal - February 11, 2021

RE:Looks interesting this a.m.....

I went in....against all my trading rules..... Sheesh. Now for the stickhandling time. Looking for support somewhere. Cheers !
Iseneschal - February 10, 2021

Looks interesting this a.m.....

In some 
Iseneschal - February 10, 2021

THis was another runner.....

scalped this sweetheart also....busy day.  Che Ching !!!!!
Iseneschal - February 9, 2021

Pdsb hoping Tuesday was the bottom

too early to tell
zen2en - December 31, 2020

Today's the day. Meet live with PDS Biotechnology CEO

Today's the day. Meet live with PDS Biotechnology CEO Frank Bedu-Addo, Ph.D. Get informed, ask questions, no charge: https...
schoolofrock - October 6, 2020
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »